Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPPBiotechnology
+$0.02 today
- Market cap
- $1.12B
- Beta
- 0.98
- P/E (TTM)
- -16.2
- EPS (TTM)
- -$2.27
Volume 0.73M
Average 0.33M
RAPP Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Rapport Therapeutics, Inc. Common StockNASDAQ: RAPP
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$255.09M, compared with -$147.81M a year earlier.
Context
- Retained earnings amounted to 51.3% of total assets at the end of Q1 FY2026, up 2.3 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -72.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (235.23M) USD
- Year-over-year change
- -90.1%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (235.23M) | -90.1% |
| FY2024 | 2024-12-31 | (123.75M) | -172.3% |
| FY2023 | 2023-12-31 | (45.44M) | -326.6% |
| FY2022 | 2022-12-31 | (10.65M) | — |
Retained Earnings vs competitors
How RAPP compares with its peers on the latest reported figures
- RAPP's Mar 2026 retained earnings of -$255.09M is the 6th highest of the 10 companies compared; the peer median is -$227.87M.
- Its year-over-year change of -72.6% is the 9th highest of 10, against a peer median of -29.8%.
- Retained earnings amounts to 51.3% of total assets for RAPP, versus a peer median of 100.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $0 | +100.0% | — | 0.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | -$148.58M | -29.8% | — | 37.8% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | -$191.84M | -43.8% | — | 73.4% |
| Mar 2026 | -$203.22M | -10.7% | — | 562.3% | |
| Mar 2026 | -$227.87M | -48.4% | — | 82.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$255.09M | -72.6% | — | 51.3% |
| Mar 2026 | -$421.19M | -90.0% | — | 100.6% | |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$1.24B | -21.9% | — | 804.3% |
| Sep 2026 | -$1.41B | -34.2% | — | 107.5% | |
| Jun 2026 | -$1.42B | -15.6% | — | 186.7% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding RAPP) | -$227.87M | -29.8% | — | 100.6% | |
Competitors are the stored peer set for RAPP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
Intrinsic Alpha fair value
Locked
Current Price
$23.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.